INTRODUCTION AND OBJECTIVES: Genomic alterations predicting response to targeted therapy are an area of active interest in developing novel therapies for patients with metastatic urothelial carcinoma (mUC) progressing after first and second-line therapy. With the objective of characterizing the frequency of actionable alterations and the evidence supporting therapy targeting these alterations, we report our experience with next-generation sequencing in mUC.
INTRODUCTION AND OBJECTIVES: Genomic alterations predicting response to targeted therapy are an area of active interest in developing novel therapies for patients with metastatic urothelial carcinoma (mUC) progressing after first and second-line therapy. With the objective of characterizing the frequency of actionable alterations and the evidence supporting therapy targeting these alterations, we report our experience with next-generation sequencing in mUC.
METHODS: Patients with sequenced mUC lesions were identified from our prospectively-maintained institutional database. All actionable alterations with clinical or biologic evidence supporting an association with response to targeted therapy were identified and stratified by OncoKB level of evidence. The relationship between strength of evidence and administration of targeted therapy was examined.
RESULTS: Ninety-nine of 134 patients (74%) harbored at least one actionable alteration, with 162 total actionable alterations identified. Twenty level 2B alterations were identified, reflecting alterations predictive of response to an FDA-approved drug in another indication, with ERBB2 amplification (9), TSC1/TSC2 (6), and BRCA1/BRCA2 mutations (3) most common. Twenty-eight level 3A and 51 level 3B alterations were identified, reflecting compelling clinical evidence supporting targeted therapy in bladder cancer and non-bladder cancer indications, respectively. Sixty-two level 4 alterations, supported by compelling biologic evidence, were also identified. Seventeen patients received targeted therapy, which was administered to 21% of patients with level 3B or higher alterations (figure).
CONCLUSIONS: Most mUC lesions harbor at least one actionable alteration, which may serve as rational targeted therapeutic opportunities in mUC. These findings highlight the need for additional clinical trials and the role of genetic testing in identifying candidates for targeted therapy. 
PD47-06 THE PROGNOSTIC SIGNIFICANCE OF THE ANDROGEN RECEPTOR GENE AND SINGLE NUCLEOTIDE POLYMORPHISMS IN ANDROGEN-REGULATED GENES IN PATIENTS WITH CONCOMITANT BLADDER AND PROSTATE CANCER
Georgios Gakis*, Tina Schubert, W€ urzburg, Germany; Maritta Munz, Arnulf Stenzl, Markus Renninger, T€ ubingen, Germany INTRODUCTION AND OBJECTIVES: There is evidence in literature which suggests that the androgen signaling pathway may exert an adverse impact on outcomes of patients with bladder cancer (BC) which may be further pronounced in those with concomitant prostate cancer (PC). Therefore, the objective of the study was to investigate the predisposing role of the activity of the androgen receptor (AR-) gene and single-nucleotide polymorphisms (SNPs) in androgenregulated genes in patients with concomitant BC and PC.
METHODS: A total of 792 genotyping analyses were conducted in 36 patients with invasive BC and incidental PC treated with radical cystoprostatectomy (RCP) between 2003 and 2008. DNA was isolated from tumor-free lymphatic tissue derived from lymph node dissection during RCP and amplified by PCR analysis. Following this, DNA sequencing was conducted to determine the specific allelic variants. Twenty-one risk SNPs located in androgen-responsive elements of the promoter region of the following genes were investigated: PSCA (rs2978974, rs2294008, rs3736001, rs1045531), NAT1 (rs15561), MYC (rs6983267), CYP17A1 (rs743572), SDR5A2 (rs676033, rs523349, rs9285858), ALPK1 (rs2051778), ARRDC3 (rs2939244), BMP5 (3734444), CASP3 (rs4862396), FBXO32 (rs7830622), FLT1 (rs9508016), IRS2 (rs7986346), SKAP1 (rs6504145), TACC2 (rs3763763), MIR151A (rs14974929) and BCN2 (rs16934641). In addition, the number of Cytosine-Adenine-Guanine (CAG) triplets in the AR gene was measured which is inversely related to the activity of the gene. Histopathologic parameters of patients were correlated with genetic findings and Kaplan-Meier analyses were conducted to evaluate the impact of the risk alleles on 3-year BC recurrence-free survival. The median follow-up was 41 months (range: 3-102).
RESULTS: The mean number AE S.E.M of CAG-triplets in the AR gene was 23AE2 (median: 24, IQR: 22-25, total range: 18-29). The presence of the rs15561 was associated with !pT3a stage at RCP (p[0.030). Lymph node positive disease was associated with the rs2051778 (p[0.020). A lower number of CAG-repeats in the ARgene (!23 vs. 22) was significantly associated with inferior RFS (27% vs. 65%; p[0.026). RFS was also significantly lower in patients with the rs2978974 allele (32% vs. 75%; p[0.015) and in those with the risk SNP rs15561 (28% vs. 65%; p[0.019).
CONCLUSIONS: These data suggest that the activity of AR gene and the specific risk SNPs in androgen-regulated genes act as predisposing factors on outcomes on patients with concomitant BC and PC. 
